INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor pipeline product SN301A due to observed dose limiting toxicities [2] - Following this announcement, Senti's stock price dropped by $1.36 per share, representing a decline of 27.2%, closing at $3.64 per share on the same day [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of advocating for victims of securities fraud and corporate misconduct [3] - The firm has a track record of recovering significant damages for class members, highlighting its expertise in handling such cases [3]